Castration Resistant Prostatic Neoplasms Recruiting Phase 1 / 2 Trials for Sacituzumab govitecan (DB12893)

Also known as: Prostate Neoplasms, Castration-resistant / Castration-Resistant Prostatic Neoplasms / Prostatic Neoplasms, Castration-Resistant

Indication	Status	Phase
DBCOND0129140 (Castration Resistant Prostatic Neoplasms)	Recruiting	1 / 2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04381832	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer	Treatment	Docetaxel (DB01248) Enzalutamide (DB08899) Etrumadenant (DB17506) Sacituzumab govitecan (DB12893) Zimberelimab (DB17505)